176 related articles for article (PubMed ID: 19440857)
21. High frequency of hand foot syndrome with capecitabine.
Kamil M; Haron M; Yosuff N; Khalid I; Azman N
J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
[TBL] [Abstract][Full Text] [Related]
22. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
23. Hand and foot syndrome secondary to capecitabine.
Lal HS
Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
[TBL] [Abstract][Full Text] [Related]
24. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
[No Abstract] [Full Text] [Related]
25. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Latif S; Fraga G; Gadzia J
J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
[TBL] [Abstract][Full Text] [Related]
26. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
27. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
[TBL] [Abstract][Full Text] [Related]
28. Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome.
Santos-Leite ÉGD; Sacramento LV; Santana AM; Dantas JBL; Carrera M; Martins GB
Braz Dent J; 2022; 33(4):97-102. PubMed ID: 36043574
[TBL] [Abstract][Full Text] [Related]
29. Candidate mechanisms for capecitabine-related hand-foot syndrome.
Milano G; Etienne-Grimaldi MC; Mari M; Lassalle S; Formento JL; Francoual M; Lacour JP; Hofman P
Br J Clin Pharmacol; 2008 Jul; 66(1):88-95. PubMed ID: 18341672
[TBL] [Abstract][Full Text] [Related]
30. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Hénin E; You B; VanCutsem E; Hoff PM; Cassidy J; Twelves C; Zuideveld KP; Sirzen F; Dartois C; Freyer G; Tod M; Girard P
Clin Pharmacol Ther; 2009 Apr; 85(4):418-25. PubMed ID: 19078948
[TBL] [Abstract][Full Text] [Related]
31. [A case of severe hand-foot syndrome caused by capecitabine].
Shimomatsuya T; Mitsudou Y; Nakamura T; Yonezawa K; Shiraishi S; Fujino M; Maruhashi K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1139-41. PubMed ID: 17637558
[TBL] [Abstract][Full Text] [Related]
32. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Sauter C; Saborowski A; Ockenfels HM
Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
[TBL] [Abstract][Full Text] [Related]
33. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
34. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
[TBL] [Abstract][Full Text] [Related]
35. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine induced cutaneous hyperpigmentation: report of a case.
Pui JC; Meehan S; Moskovits T
J Drugs Dermatol; 2002 Sep; 1(2):202-5. PubMed ID: 12847748
[TBL] [Abstract][Full Text] [Related]
37. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Maino KL; Norwood C; Stashower ME
Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
[TBL] [Abstract][Full Text] [Related]
38. [Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
Kuji M; Masuko H; Yamagami H; Matsumoto S; Tanioka T; Takahashi S; Ishizu H; Takahashi M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1752-4. PubMed ID: 25731318
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine and Hand-foot Syndrome: A Case Report.
Uppala PK; Varghese AM; Yella SST; Velmurugan H; Thangaraju P; Krishna Sasanka KSBS
Infect Disord Drug Targets; 2023; 23(1):e140622205973. PubMed ID: 35708076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
